Get the Stockscreener App
5.41
4.86%
-0.16
Cumberland Pharmaceuticals Inc stock is traded at $5.41, with a volume of 33,538.
It is down -4.86% in the last 24 hours and up +14.20% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$5.57
Open:
$5.59
24h Volume:
33,538
Relative Volume:
0.01
Market Cap:
$77.67M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-7.411
EPS:
-0.73
Net Cash Flow:
$-1.00M
1W Performance:
-19.83%
1M Performance:
+14.20%
6M Performance:
+310.78%
1Y Performance:
+192.77%
1-Day Range:
$5.19
$5.59
1-Week Range:
$4.64
$6.70
52-Week Range:
$1.04
$7.25
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
5.41 | 77.67M | 37.79M | -10.38M | -1.00M | -0.73 |
|
ZTS
Zoetis Inc
|
160.05 | 72.14B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.04 | 47.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.76B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.31 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cumberland Pharma, Janssen R&D, Cephalon - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
Earnings call transcript: Cumberland Q4 2024 results show revenue rise By Investing.com - Investing.com Australia
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World
Cumberland Pharmaceuticals Inc. (CPIX) reports earnings - Quartz
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2024 Earnings Call Transcript - MSN
Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharma stock soars to 52-week high of $7.25 By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals: Key Insights from Earnings Call - TipRanks
Cumberland Pharma stock soars to 52-week high of $7.25 - Investing.com India
Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ... By GuruFocus - Investing.com Canada
Cumberland: Q4 Earnings Snapshot - Midland Daily News
Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Advances - TipRanks
Earnings call transcript: Cumberland Q4 2024 results show revenue rise - Investing.com
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth - TradingView
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth -March 04, 2025 at 04:52 pm EST - Marketscreener.com
Cumberland: Q4 Earnings Snapshot -March 04, 2025 at 04:51 pm EST - Marketscreener.com
Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - BioSpace
Glenmark Pharmaceuticals Acquires & Launches Acetylcysteine Injection In The U.S. - BW Healthcare World
Glenmark acquires Acetylcysteine injection, launches in US market - BusinessLine
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117% - Simply Wall St
Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS - Quantisnow
When Will Cumberland Pharmaceuticals Reveal Its 2024 Performance? Key Date for Specialty Pharma Investors - StockTitan
(CPIX) Trading Report - Stock Traders Daily
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet? - Simply Wall St
Cumberland Pharma stock soars to 52-week high of $6.43 By Investing.com - Investing.com South Africa
Cumberland Pharma stock soars to 52-week high of $6.43 - Investing.com
Cumberland Pharmaceuticals' Pneumonia Injection Receives Approval in China -February 18, 2025 at 08:19 am EST - Marketscreener.com
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - Finansavisen
Corneal Ulcer Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, NDA Approval, Prevalence, Incidence, Therapies, and Companies by DelveInsight - The Globe and Mail
Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Decreases By 56.3% - MarketBeat
Cumberland Pharmaceuticals Inc. Receives Notification from the U.S. Food and Drug Administration - Marketscreener.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated at StockNews.com - MarketBeat
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Cumberland Pharmaceuticals ups common stock offering - MSN
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
An Analysis of Cumberland Pharmaceuticals Inc (CPIX)’s Potential Price Growth - Knox Daily
Future Outlook And Stock Price Performance For Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) - Marketing Sentinel
Cumberland Pharmaceuticals Inc (CPIX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Cumberland Pharmaceuticals Inc (CPIX) Shares Down Despite Recent Market Volatility - The News Heater
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):